Application Note Archives - Touchlight https://touchlight.com/tag/application-note/ DNA is our DNA™ Wed, 08 Apr 2026 12:24:38 +0000 en-US hourly 1 https://touchlight.com/wp-content/uploads/2025/06/cropped-Favicon-32x32.png Application Note Archives - Touchlight https://touchlight.com/tag/application-note/ 32 32 Boosting Lentiviral Vector Yields with dbDNA™ and Fugene® 4K Transfection Reagent https://touchlight.com/boosting-lentiviral-vector-yields-with-dbdna-and-fugene-4k-transfection-reagent/ Wed, 08 Apr 2026 12:23:56 +0000 https://touchlight.com/?p=5677 The post Boosting Lentiviral Vector Yields with dbDNA™ and Fugene® 4K Transfection Reagent appeared first on Touchlight.

]]>
Application Note
5 mins
Lentivirus

Boosting Lentiviral Vector Yields with dbDNA™ and Fugene® 4K Transfection Reagent

This application note presents a comparative study of enzymatically manufactured doggybone DNA™ (dbDNA™) versus traditional plasmid DNA (pDNA) for lentiviral vector (LVV) production, using the FuGENE® 4K transfection reagent. The study evaluates transient transfection of third‑generation lentiviral systems in HEK293T cells, assessing performance across both adherent and suspension culture processes relevant to scalable LVV manufacturing.

The document details experimental results showing that dbDNA, when used with FuGENE® 4K, delivers higher infectious lentiviral titres than pDNA across multiple transfection conditions. Up to three‑fold higher titres were achieved in adherent cultures, with 2.4‑fold higher titres in suspension systems, alongside improved performance at lower DNA inputs. The findings also highlight cost‑of‑goods advantages and the suitability of dbDNA’s cell‑free, fermentation‑free manufacturing process for research and GMP‑aligned LVV production.

Download this application note to:

  • Review comparative data on dbDNA vs pDNA performance in lentiviral vector production
  • Learn how transfection parameters impact LVV yield in adherent and suspension HEK293T systems
  • Understand the yield, scalability, and cost implications of using dbDNA with FuGENE® 4K

Access the application note here:

The post Boosting Lentiviral Vector Yields with dbDNA™ and Fugene® 4K Transfection Reagent appeared first on Touchlight.

]]> Unlocking AAV gene therapy cost of goods savings with dbDNA™: A comparative analysis with plasmid DNA https://touchlight.com/unlocking-aav-gene-therapy-cost-of-goods-savings-with-dbdna-a-comparative-analysis-with-plasmid-dna/ Wed, 11 Mar 2026 20:09:17 +0000 https://touchlight.com/?p=5584 The post Unlocking AAV gene therapy cost of goods savings with dbDNA™: A comparative analysis with plasmid DNA appeared first on Touchlight.

]]>
Application Note
4 mins
AAV

Unlocking AAV gene therapy cost of goods savings with dbDNA™: A comparative analysis with plasmid DNA

This application note presents an independent cost-of-goods (COG) analysis conducted by Decisional Point Limited to evaluate the financial impact of switching from plasmid DNA (pDNA) to Touchlight’s enzymatically produced dbDNA™ for AAV manufacturing. Leveraging an established AAV bioprocess economic model, the study compares baseline COG for dbDNA™ versus pDNA and explores multiple scenario analyses, including dose size, GMP DNA cost, and transfection material requirements to assess their influence on total COG, COG per dose, and COG across key process steps.

The results demonstrate a significant reduction in manufacturing COG when using dbDNA™, highlighting meaningful potential savings for AAV gene therapy developers.

Download the application note to explore the complete analysis and findings.

Access the application note here:

The post Unlocking AAV gene therapy cost of goods savings with dbDNA™: A comparative analysis with plasmid DNA appeared first on Touchlight.

]]> Improve your RNA quality with z- dbDNA™, an optimal IVT template for superior RNA purity and low dsRNA content https://touchlight.com/improve-your-rna-quality-with-z-dbdna/ Tue, 09 Dec 2025 08:14:18 +0000 https://touchlight.upthere.studio/?p=1436 The post Improve your RNA quality with z- dbDNA™, an optimal IVT template for superior RNA purity and low dsRNA content appeared first on Touchlight.

]]>
Application Note
4 mins
mRNA

Improve your RNA quality with z- dbDNA™, an optimal IVT template for superior RNA purity and low dsRNA content

As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements. Touchlight’s z- dbDNA technology delivers a groundbreaking alternative, enabling rapid, high-quality RNA manufacturing with unmatched purity and scalability.

This application note explores how Touchlight’s z- dbDNA transforms RNA vaccine and therapeutic development, offering a cost-effective, efficient solution to empower innovation across mRNA, self-amplifying RNA (saRNA), and more.

What You’ll Learn:
  • How Touchlight’s z- dbDNA overcomes challenges in RNA manufacturing
  • The benefits of synthetic DNA for RNA-based therapeutics
  • Why Touchlight’s z- dbDNA is ideal for scalable mRNA and saRNA production

Access the application note here:

The post Improve your RNA quality with z- dbDNA™, an optimal IVT template for superior RNA purity and low dsRNA content appeared first on Touchlight.

]]> Advancing Lentiviral Vector Manufacturing using dbDNA™ across LVV system generations https://touchlight.com/advancing-lentiviral-vector-manufacturing-using-dbdnatm-across-lvv-system-generations/ Mon, 27 Oct 2025 21:07:34 +0000 https://touchlight.com/?p=5118 The post Advancing Lentiviral Vector Manufacturing using dbDNA™ across LVV system generations appeared first on Touchlight.

]]>
Application Note
5 mins
Lentivirus

Advancing Lentiviral Vector Manufacturing using dbDNA™ across LVV system generations

This application note highlights the advantages of dbDNA™, a linear, enzymatically amplified DNA construct, as a cell-free alternative to plasmid DNA (pDNA) for lentiviral vector (LVV) production. Manufactured under GMP using a rapid, scalable, and high-fidelity process free from animal-derived components, dbDNA eliminates the need for bacterial fermentation and master cell banks, significantly reducing the risk of bacterial impurities.

Expression Manufacturing evaluated dbDNA against pDNA in both 3rd-generation and LentET 2.5 LVV systems using ET3 and GFP transgenes. Results demonstrated higher infectious titres and an improved safety profile with dbDNA, underscoring its potential to enhance LVV yields and reduce cost of goods through optimised transfection efficiency.

Download the application note to learn:

  • How dbDNA supports both 2.5th and 3rd generation LVV systems, demonstrating flexibility across vector design platforms
  •  The potential for reduced cost of goods in LVV manufacturing due to dbDNA’s lower DNA input requirements and streamlined production
  • Experimental results showing up to 40% higher infectious titres with dbDNA packaging constructs compared to pDNA when using a clinical-stage transgene

Download the application note here:

The post Advancing Lentiviral Vector Manufacturing using dbDNA™ across LVV system generations appeared first on Touchlight.

]]>